Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases
TV Masyuk, BN Radtke, AJ Stroope, JM Banales… - Hepatology, 2013 - journals.lww.com
In polycystic liver (PLD) and kidney (PKD) diseases, increased cyclic adenosine
monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated
cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin
analog that preferentially binds to SSTR2) inhibits cyst growth. Here we compare the effects
of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor
specificity) on:(1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using …
monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated
cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin
analog that preferentially binds to SSTR2) inhibits cyst growth. Here we compare the effects
of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor
specificity) on:(1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using …